Screening a Library of FDA-Approved and Bioactive Compounds for Antiviral Activity against SARS-CoV-2SARS-CoV-2에 대한 항바이러스 활성에 대한 FDA 승인 및 생리활성 화합물 라이브러리 스크리닝Article Published on 2021-08-132022-09-11 Journal: ACS Infectious Diseases [Category] SARS, 신약개발, 치료제, [키워드] activity acute respiratory syndrome acute respiratory syndrome coronavirus anti-inflammatory activity Antiviral antiviral activity antivirals approved assays B02 causative agent combination therapies combination therapy Compound compound screening coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 pandemic Critical death demonstrated drug Drug repurposing effective epithelial cells exhibit FDA Health highlight highlighting Host identify include inhibitor kinase kinases library mono pathway protease Proteases Rad51 Remdesivir reported Safe SARS-CoV-2 SARS-CoV-2 replication Screening Seven severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 starting point synergy therapeutic options treat [DOI] 10.1021/acsinfecdis.1c00017 PMC 바로가기 [Article Type] Article
Editorial: Tocilizumab, a Humanized Therapeutic IL-6 Receptor (IL-6R) Monoclonal Antibody, and Future Combination Therapies for Severe COVID-19사설: Tocilizumab, 인간화 치료 IL-6 수용체(IL-6R) 단클론항체 및 중증 COVID-19에 대한 미래 조합 요법Editorial Published on 2021-07-192022-09-12 Journal: Medical science monitor : international medical jo [Category] 진단, [키워드] antibody approved authorization CAR chimeric antigen receptor clinical development clinical trial combination therapies combination treatment COVID-19 COVID-19 therapy CRS Cytokine release syndrome develop disease drug editorial Efficacy Emergency EUA FDA food Future giant cell arteritis Hospital admission hospitalized patient humanized humanized monoclonal antibody IL-6 IL-6 receptor IL-6R Immunosuppressed individual infected with SARS-CoV-2 juvenile idiopathic arthritis moderate monoclonal antibody Patient Proinflammatory cytokine recovery reduce REMAP-CAP rheumatoid arthritis SARS-COV-2 infection severe COVID-19 severity of COVID-19 supported systemic effect T-cell therapeutic Tocilizumab treat Treatment [DOI] 10.12659/MSM.933973 PMC 바로가기 [Article Type] Editorial
Low-Dose Tocilizumab With High-Dose Corticosteroids in Patients Hospitalized for COVID-19 Hypoxic Respiratory Failure Improves Mortality Without Increased Infection RiskCOVID-19 저산소 호흡기로 입원 한 환자에서 고용량 코르티코 스테로이드가있는 저용량 토 실리 주맙Multicenter Study Published on 2021-06-282022-09-01 Journal: The Annals of Pharmacotherapy [Category] MERS, 진단, [키워드] 28-day mortality 95% CI Adult patients adult respiratory distress syndrome Analysis balance benefit Biomarker Combination combination therapies combination therapy Corticosteroid Corticosteroids COVID-19 COVID-19 pneumonia COVID-19 treatment Dexamethasone dexamethasone 6 mg dosage failure group hazard ratio high mortality hypoxia hypoxic respiratory failure Increased Infection Inflammation Interleukins medication therapy management Modification Mortality objective Patient patients with COVID-19 Pneumonia present reduction in mortality Relative risk Relevance respiratory Respiratory failure respiratory infections Result Retrospective study risk risk of infection Secondary infection severe respiratory failure Standard of care steroid supportive therapy survival therapeutic effect therapy Tocilizumab Treatment was performed were assessed [DOI] 10.1177/10600280211028882 PMC 바로가기 [Article Type] Multicenter Study
Drug repurposing screens identify chemical entities for the development of COVID-19 interventions약물 용도 스크린 스크린은 Covid-19 개입의 개발을위한 화학 기관을 식별합니다.Article Published on 2021-06-032022-08-31 Journal: Nature Communications [Category] MERS, SARS, 변종, 신약개발, 임상, 진단, 치료기술, 치료법, 치료제, [키워드] ACE2 acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Antiviral antiviral activity block Calu-3 calu-3 cells candidate caused Cell cell line cell lines class combination therapies Compound compounds coronavirus COVID-19 direct-acting antiviral Direct-acting antivirals drug library Drug repurposing expressing hamsters HeLa cell HeLa cells high-content imaging High-throughput screening Host host cell identify in vitro activity Infection inhibiting inhibitors inhibitors of SARS-CoV-2 Intervention lung epithelial mechanism nelfinavir pandemic parent pharmacokinetic primary cell prodrug profiles Prophylactic receptor ACE2 reduce respiratory SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 receptor SARS-CoV-2 replication sensitivity targets therapeutic drug Viral viral infection virus entry [DOI] 10.1038/s41467-021-23328-0 PMC 바로가기 [Article Type] Article
COVID-19 as a mediator of interferon deficiency and hyperinflammation: Rationale for the use of JAK1/2 inhibitors in combination with interferonReview Published on 2021-04-142023-06-15 Journal: Cytokine & growth factor reviews [Category] MERS, SARS, [키워드] Baricitinib combination therapies COVID-19 hydroxyurea hyperinflammation Inflammatory cytokines Interferon-alpha2 Interferon-beta JAK1/2 inhibitor NETosis ruxolitinib SARS-CoV-2 statins thrombosis Treatment Type I interferon deficiency [DOI] 10.1016/j.cytogfr.2021.03.006 PMC 바로가기 [Article Type] Review
Xylopic acid-amodiaquine and xylopic acid-artesunate combinations are effective in managing malaria in Plasmodium berghei -infected mice자일로픽산-아모디아퀸 및 자일로픽산-아르테수네이트 조합은 플라스모디움 베르헤이 감염 쥐에서 말라리아 관리에 효과적입니다.Research Published on 2021-02-252024-08-08 Journal: Malaria Journal [Category] 말라리아, [키워드] amodiaquine Antimalarial drugs artesunate combination therapies Isobolographic analysis Plasmodium berghei synergism Xylopic acid [DOI] 10.1186/s12936-021-03658-6 PMC 바로가기 [Article Type] Research
Hepatocellular carcinoma Reviews Published on 2021-01-212022-10-05 Journal: Nature Reviews Disease Primers [Category] 바이오마커, 변종, 신약개발, 치료제, [키워드] accelerated Anti-VEGF approved bevacizumab biopsies Cancer Clinical practice Combination combination therapies criteria Diabetes Mellitus Efficacy Evidence expected FDA approval HCC Health Hepatitis B virus hepatitis C virus Immunotherapy impacted incidence information inhibitor Liver cancer management molecular mutations New Non-invasive outcome Pathogenesis Patient phase III trial regimens risk factor sorafenib stages steatohepatitis syndrome Therapies therapy tissue translated Trial tyrosine kinase inhibitor unique West [DOI] 10.1038/s41572-020-00240-3 [Article Type] Reviews
Trends and strategies to combat viral infections: A review on FDA approved antiviral drugsReview Published on 2021-01-142024-09-02 Journal: International journal of biological macromolecules [Category] 대상포진, [키워드] antiviral drugs combination therapies entry inhibitors NNRTIs NRTIs protease inhibitors Virus pandemics [DOI] 10.1016/j.ijbiomac.2021.01.076 PMC 바로가기 [Article Type] Review
Repurposing Antimalarials to Tackle the COVID-19 PandemicCOVID-19 전염병에 대처하기 위해 항말라리아제의 용도 변경Review Published on 2021-01-012022-08-31 Journal: Trends in parasitology [Category] SARS, 신약개발, 치료제, [키워드] acts acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Anti-inflammatory effects antimalarial Antiviral Artemisinin artemisinins artesunate artesunate/pyronaridine Clinical studies clinical study combination therapies combination therapy coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 infections cytokine Cytokine storm demonstrated Drug repurposing Effectiveness Evidence IL-6 in vitro interleukin interleukin-6 pyronaridine repurposing respiratory SARS-CoV-2 severe acute respiratory syndrome Coronavirus severe coronavirus disease shown Support [DOI] 10.1016/j.pt.2020.10.003 PMC 바로가기 [Article Type] Review
Genetic background and PfKelch13 affect artemisinin susceptibility of PfCoronin mutants in Plasmodium falciparum유전적 배경과 PfKelch13은 Plasmodium falciparum에서 PfCoronin 돌연변이의 artemisinin 감수성에 영향을 미칩니다Research Article Published on 2020-12-282022-09-06 Journal: PLoS Genetics [Category] Communicable Disease, [키워드] Affect African Analysis Artemisinin Asia Biology can not clinical isolates combination therapies combination therapy continent develop domain drug pressure drug resistance Effect elevated Evidence evidence of Evolution focus Future Genetic genetic analysis genetic background genetic determinant genetic determinants Health in vitro independent isolate Laboratory malaria Mask mutant Mutation no evidence of parasite parasites pathway phenotype Plasmodium falciparum Protein reduced referred to representing selected selection pressure South America Spread standard treatment strain survival susceptibility synergy tested Transmission [DOI] 10.1371/journal.pgen.1009266 PMC 바로가기 [Article Type] Research Article